Pfizer (NYSE: PFE) CEO Ian Read has gone about remaking the pharma-based conglomerate into a leaner, more focused company. In advance of reporting second-quarter results, Pfizer announced a new re-organization.
Pfizer management has used the terms "innovative" business and "value" business on previous conference calls, so while this shake-up isn't a surprise, the groupings are given that we have three units instead of two. Innovative 1 is a broad swath of branded pharma products, while Innovative 2 is vaccines, oncology, and consumer health care. Finally, there is Value, which is all established -- e.g., no longer patent-protected products -- or those products losing patent protection by 2015.
In this video, health care analyst David Williamson discusses what these events mean for investors in Pfizer and whether a bigger break-up of the company is at hand.
Rising health care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health care system -- and how to potentially profit from this trend -- click here for free, immediate access.
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...